L04AA06 • mycophenolate • Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants
Mycophenolate is an immunosuppressive medication used to prevent organ rejection in transplant recipients, such as kidney, liver, or heart transplants. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids. Mycophenolate works by inhibiting the proliferation of T and B lymphocytes, thereby reducing the immune response against the transplanted organ.
Mycophenolate is available as mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), both of which are taken orally, usually twice daily, as directed by a doctor. The exact dosage depends on the type of transplant and the patient’s condition.
Common side effects include nausea, diarrhea, vomiting, abdominal pain, and infections, as the medication suppresses the immune system. Other side effects may include anemia, leukopenia (low white blood cell count), and an increased risk of severe or opportunistic infections.
Mycophenolate is contraindicated in pregnant women, as it can cause severe birth defects. Women of childbearing age must use effective contraception during treatment and for several weeks after stopping the medication. Regular monitoring is essential to detect potential side effects and adjust the dosage if necessary.
Substance: mycophenolate
Date of last drug list: 01-07-2013
Commercial code: W42264002
Concentration: 180mg
Pharmaceutical form: gastro-resistant film tablets
Quantity: 100
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: NOVARTIS PHARMA GMBH - GERMANIA
Holder: NOVARTIS PHARMA GMBH - GERMANIA
Number: 8649/2016/02
Shelf life: 30 months